Horizon Therapeutics PLC (HZNP) News

Horizon Therapeutics PLC (HZNP): $116.30

0.05 (+0.04%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add HZNP to Watchlist
Sign Up

Filter HZNP News Items

HZNP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HZNP News Highlights

  • HZNP's 30 day story count now stands at 10.
  • Over the past 23 days, the trend for HZNP's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about HZNP are BIO, EYE and TOP.

Latest HZNP News From Around the Web

Below are the latest news stories about HORIZON THERAPEUTICS PUBLIC LTD CO that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Rule 17(e) Announcement - Horizon Therapeutics plc

DUBLIN, October 06, 2023-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Yahoo | October 6, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

DUBLIN, October 03, 2023--IRISH TAKEOVER PANEL

Yahoo | October 3, 2023

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

DUBLIN, October 02, 2023--Horizon Therapeutics plc announces new UPLIZNA data in neuromyelitis optica spectrum disorder (NMOSD) to be presented at ECTRIMS 2023.

Yahoo | October 2, 2023

New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes

DUBLIN, September 29, 2023--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at American Thyroid Association (ATA) 2023.

Yahoo | September 29, 2023

Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry

DUBLIN, September 26, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to U.S. News & World Report’s 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing.

Yahoo | September 26, 2023

The Hedge Fund That Made a Killing Betting Against Lina Khan

The efforts by Federal Trade Commission Chair Lina Khan to protect Main Street are inadvertently enriching some on Wall Street, generating outsize profits for Pentwater Capital Management and other large hedge funds that bet on merger deals. In both cases, the FTC’s intervention spooked investors and sent shares of the target companies swinging.

Yahoo | September 24, 2023

FTC chair targets deals that have fallen in agency's 'blind spots'

FTC chair Lina Khan has her sights focused on challenging mergers & acquisitions in the healthcare and tech sectors, specifically those valued under $100 million. Khan argues that these mergers can snowball into larger monopolies when left unchecked. Senior Reporter for Yahoo Finance Anjalee Khemlani joins to breakdown Lina Khan's recent statement at the Oliver Wyman Health Innovation Summit in Chicago.

Yahoo | September 19, 2023

Healthcare: FTC Chair Lina Khan to crack down on 'below radar' deals

FTC Chair Lina Khan wants to help create more competition in the market and avoid monopolies.

Yahoo | September 19, 2023

Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List

DUBLIN, September 19, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2023 list in the large company category. This is the seventh consecutive year Horizon has been named to the list and the company’s fourth time ranking No. 1.

Yahoo | September 19, 2023

The 3 Most Undervalued Biotech Stocks to Buy in September 2023

While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners.

Joel Baglole on InvestorPlace | September 13, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!